Skip to main content

Celularity Promotes Two Executives in Executive Leadership Team

FLORHAM PARK, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placenta-derived allogeneic cell therapies, announced the promotion of two senior executives and the formation of a new Executive Committee.

John R. Haines was named Senior Executive Vice President, General Manager and Chief Administrative Officer, having served previously as Chief Operating Officer. Brad Glover, Ph.D., was named Executive Vice President and Chief Operating Officer, having served previously as Executive Vice President and Chief Technical Officer. Both Mr. Haines and Dr. Glover will serve on a newly formed Executive Committee under Robert J. Hariri, M.D., Ph.D., Celularity’s Chair, Chief Executive Officer, and Founder.

Mr. Haines joined our company in September 2017 as Executive Vice President and Chief Administrative Officer and was named Chief Operating Officer in October 2020, a role he continued at Celularity following the July 2021 business combination. In his new role, Mr. Haines will lead Celularity’s internationalization and global expansion strategy. He will also be responsible for business and administrative operations and strategic initiatives, including mergers, acquisitions and divestitures. Mr. Haines holds graduate degrees from the University of Pennsylvania, the University of Pennsylvania Graduate School of Medicine, and King’s College, London, and earned a postgraduate diploma from Stanford University. He is an honors graduate of Villanova University, where he earned a B.A. in Economics.

Dr. Glover joined our company in March 2021 as Executive Vice President and Chief Technology Officer, a role he continued at Celularity following the July 2021 business combination. In his new role as Chief Operating Officer, Dr. Glover will take on additional responsibilities including corporate strategic planning, strategic and operational decision-making, corporate oversight, human resources and enterprise expansion. Dr. Glover holds a Ph.D. in biochemistry and molecular genetics from the University of Colorado, an M.B.A. from the Rady School of Management at the University of California, San Diego, and a Bachelor of Science degree in biochemistry from the University of California, San Diego. Dr. Glover was also a Jane Coffin Childs Medical Research Fellow at the University of California, Berkeley.

“John and Brad bring proven leadership at Celularity as we map and execute the expansion of our cell therapy and biomaterials businesses, including outside the United States,” said Robert J. Hariri, M.D., Ph.D., Celularity’s Chair, Chief Executive Officer, and Founder, adding, “I look forward to the contributions they will continue to make in their expanded roles.”

About Celularity

Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs). These therapeutic programs target indications in cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

To learn more, visit celularity.com.

Celularity Investor Contacts:
Carlos Ramirez SVP, Investor Relations
Celularity Inc.
carlos.ramirez@celularity.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.